15 research outputs found

    Heavy Resistance Exercises

    Get PDF

    Large expert-curated database for benchmarking document similarity detection in biomedical literature search

    Get PDF
    Document recommendation systems for locating relevant literature have mostly relied on methods developed a decade ago. This is largely due to the lack of a large offline gold-standard benchmark of relevant documents that cover a variety of research fields such that newly developed literature search techniques can be compared, improved and translated into practice. To overcome this bottleneck, we have established the RElevant LIterature SearcH consortium consisting of more than 1500 scientists from 84 countries, who have collectively annotated the relevance of over 180 000 PubMed-listed articles with regard to their respective seed (input) article/s. The majority of annotations were contributed by highly experienced, original authors of the seed articles. The collected data cover 76% of all unique PubMed Medical Subject Headings descriptors. No systematic biases were observed across different experience levels, research fields or time spent on annotations. More importantly, annotations of the same document pairs contributed by different scientists were highly concordant. We further show that the three representative baseline methods used to generate recommended articles for evaluation (Okapi Best Matching 25, Term Frequency-Inverse Document Frequency and PubMed Related Articles) had similar overall performances. Additionally, we found that these methods each tend to produce distinct collections of recommended articles, suggesting that a hybrid method may be required to completely capture all relevant articles. The established database server located at https://relishdb.ict.griffith.edu.au is freely available for the downloading of annotation data and the blind testing of new methods. We expect that this benchmark will be useful for stimulating the development of new powerful techniques for title and title/abstract-based search engines for relevant articles in biomedical research.Peer reviewe

    Tilrettelegging av praksis i hjemmesykepleie for utenlandsstudenter. Et samarbeidprosjekt mellom Utviklingssenter for hjemmetjenester i Bærum kommune og Diakonhjemmet Høgskole

    Get PDF
    Det stilles krav til at høgere utdanningssteder skal ha utveksling av studenter til andre land. Mens mange norske velger å studere helse- og sosialfag i utlandet er det bare få utenlandske studenter som tar disse fagene i Norge. Utfordringer med å tilrettelegge for en god kommunikasjon i praksisstudiene, viser seg å være en viktig årsak til dette

    Major challenges and opportunities in silicon solar module recycling

    No full text
    This article examines some of the basic questions about silicon module recycling: (1) What can be recovered from silicon modules? (2) What recycling technologies are needed? (3) What are the potential revenues for different recycling scenarios? And (4) what are the major challenges for different recycling scenarios? Three recycling scenarios are considered: module reuse, component extraction, and material extraction. Recycling process sequences for different scenarios are outlined. The discussions conclude that module reuse generates the highest revenue with the fewest processing steps, while material extraction leads to the lowest revenue with the most processing steps. It is suggested that gentle and clean separation of silicon solar cells from the glass pane is a critical technology for silicon module recycling. It is also argued that two low-concentration metals must be recovered from silicon modules: silver as a scarce material and lead as a toxic material. Their recovery requires chemical methods, while bulky materials including glass cullet, aluminum frame, and copper wiring can be recovered with physical methods. The silicon in the cells can be extracted with different qualities: ferro-silicon, metallurgical-grade silicon, or solar-grade silicon, with a higher revenue and more complicated recycling process for purer silicon. Markets outside the solar industry for the recovered silicon should be explored. The biggest challenge for module reuse is to find a large and sustained market for hundreds of gigawatts peak of decommissioned modules a year, and the biggest challenge for component extraction is the many different module and cell structures on the market and cell efficiency variability. For all the three scenarios, the cost of collecting and processing waste modules is a common challenge

    Major challenges and opportunities in silicon solar module recycling

    No full text
    This article examines some of the basic questions about silicon module recycling: (1) What can be recovered from silicon modules? (2) What recycling technologies are needed? (3) What are the potential revenues for different recycling scenarios? And (4) what are the major challenges for different recycling scenarios? Three recycling scenarios are considered: module reuse, component extraction, and material extraction. Recycling process sequences for different scenarios are outlined. The discussions conclude that module reuse generates the highest revenue with the fewest processing steps, while material extraction leads to the lowest revenue with the most processing steps. It is suggested that gentle and clean separation of silicon solar cells from the glass pane is a critical technology for silicon module recycling. It is also argued that two low-concentration metals must be recovered from silicon modules: silver as a scarce material and lead as a toxic material. Their recovery requires chemical methods, while bulky materials including glass cullet, aluminum frame, and copper wiring can be recovered with physical methods. The silicon in the cells can be extracted with different qualities: ferro-silicon, metallurgical-grade silicon, or solar-grade silicon, with a higher revenue and more complicated recycling process for purer silicon. Markets outside the solar industry for the recovered silicon should be explored. The biggest challenge for module reuse is to find a large and sustained market for hundreds of gigawatts peak of decommissioned modules a year, and the biggest challenge for component extraction is the many different module and cell structures on the market and cell efficiency variability. For all the three scenarios, the cost of collecting and processing waste modules is a common challenge

    Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

    No full text
    Summary: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union’s Horizon 2020 research and innovation programme and EFPIA
    corecore